



ጤና ሚኒስቴር - ኢትዮጵያ
MINISTRY OF HEALTH-ETHIOPIA
የዜጎች ጤና ለሃገር ብልፅግና
HEALTHIER CITIZENS FOR PROSPEROUS NATION



የኢትዮጵያ የሕብረተሰብ ጤና ኢንስቲትዩት
ETHIOPIAN PUBLIC HEALTH INSTITUTE

PUBLIC HEALTH EMERGENCY OPERATIONS CENTER (PHEOC), ETHIOPIA

COVID-19 PANDEMIC PREPAREDNESS AND RESPONSE DAILY SITUATION REPORT ETHIOPIA

(Data reported as at 16:30hrs EAT (GMT+3), 10 April 2020)

10 April 2020

ISSUE
No

78

HIGHLIGHTS




- There are 9 newly detected COVID-19 cases bringing the total confirmed cases to 65 in the country.
- One new COVID-19 related death has occurred bringing a total death to 3.
- There are 6 newly recovered COVID-19 cases bringing the total recovered cases to 10 in the country.
- Of 41 new rumors /alerts were received today, 11 of them fulfill the suspected case definition.
- 2 close contacts of confirmed cases developed COVID-19 suggestive symptoms.
- 65 new contacts of confirmed cases have been identified today bringing the number of contacts identified so far to about 1,217.
- 442 COVID-19 laboratory samples were analyzed within the last 24 hours. Of these 9-positive detected.

COVID-19 NATIONAL UPDATE

1,936 PASSENGERS UNDER MANDATORY QUARANTINE	125 TRAVELERS UNDER PHONE FOLLOW UP	909 RUMORS/ALERTS RECEIVED AND INVESTIGATED	1217 CONTACTS OF THE CONFIRMED CASES
500 SUSPECTED CASES DETECTED	65 TOTAL CONFIRMED CASE	10 TOTAL RECOVERED	3 TOTAL DEATH

COVID-19 GLOBAL UPDATE

Access link for WHO COVID-19 monitoring dashboard: <https://who.sprinklr.com/>



MAJOR COVID-19 PREPAREDNESS AND RESPONSE EFFORTS IN ETHIOPIA

BACKGROUND

Ethiopia activated its IMS under the national PHEOC. WHO and its partners are currently supporting in scaling up preparedness efforts and implementation of related recommendations suggested by the IHR Emergency Committee. Different layer so coordination platform revitalized and the PHEOC is working collaboratively with various agency representative, Partners, Embassies, hospitality sector, Industrial parks and others. There is strong communication and updating from other countries through IHR-NFPs. The sub-national level is well engaged in the preparedness and response efforts. Joint regular media briefing sessions are being conducted.


COORDINATION and COLLABORATION:

- Daily morning and evening briefing of the IMS core staffs and agency representatives is being conducted on daily basis.
- Zoom meeting conducted to update partners and discuss on the response efforts by consolidating supports from all partners and stakeholders.

EPIDEMIOLOGY and LABORATORY SURVEILLANCE

Confirmed COVID-19 cases and death:

- There are 9 newly detected COVID-19 case bringing the total confirmed cases to 65 in the country.
- Ten of the COVID-19 confirmed cases have recovered.
- One confirmed COVID-19 case who was getting medical care in Intensive Care Unit died today




COVID-19 Confirmed Cases Summary Dashboard as of April 10, 2020

Total Confirmed Cases in Ethiopia


65

COVID-19 Confirmed Cases by Gender




of Confirmed Cases by Source of Reporting/Rumor and Travel History in the last 14 days

Travel History in the last 14 days: No (Blue), Yes (Red)




Confirmed Cases by Source of Infection




of Confirmed Cases by Region and Source of infection

Source of infection: Contact (Blue), Imported (Dark Blue), Not Identified (Orange)




of Confirmed Cases by Occupation and Close contact with Cases

Close contact with Cases: No (Blue), Unknown (Dark Blue), Yes (Orange)



of Confirmed Cases by Country Travelled and Symptomatic

Symptomatic: No (Yellow), Yes (Orange)



Age Range of Confirmed Cases (Years)

Min. Age

0.8

Max. Age

85.0


of Confirmed Cases by Cough

Cough: Yes (Red), No (Blue)




of Confirmed Cases by Fever

Fever: Yes (Red), No (Blue)




of Confirmed Cases by Nationality and Close contact with Confirmed

Close contact with Confirmed: No (Blue), Unknown (Dark Blue), Yes (Orange)




of Confirmed Cases by Source of infection

Source of infection: Imported (Yellow), Contact (Red), Not Identified (Orange)




of Confirmed Cases by Symptomatic and Outcome status

Outcome status: Alive (Blue), Death (Dark Blue), Transfer out (Orange)




of Confirmed Cases by Symptomatic and Health facility visit before onset

Health facility visit before onset: No (Blue), Yes (Dark Blue)




of Confirmed Cases by Outcome status

Outcome status: Alive (Blue), Death (Dark Blue), Transfer out (Orange)



of Cases with Contact by Close Contact with Cases

Close contact with Cases: Yes (Red), No (Blue), Unknown (Orange)







Fig: Epi-Curve of the confirmed case by the date of confirmation

Laboratory test:

- 442 laboratory samples are tested for COVID-19 in the last 24 hours
- Of these samples tested 9 are found positive and 433 are negative
- 3231 COVID-19 laboratory samples are tested so far.

Contact tracing and follow-up:

- As of April 10, 2020:
 - A total of 1217 (65 new) contacts of confirmed cases have been identified.
 - 457 (11 new) have completed the 14 days follow-up, while 747 contacts are still on follow-up.
 - 56 (2 new) contacts developed COVID-19 suggestive symptoms.
 - 16 of the symptomatic and 4 asymptomatic contacts were tested positive, which are among the currently existing confirmed positive cases.



Rumors collection and verification from all sources

- As of April 10, 2020:
 - 909 rumors/alerts have been received and investigated. Of these, 41 rumors (14 via the call center) are reported today.
 - 500 rumors/alerts (11 new) have fulfilled the suspected case definition.
- On April 10, 2020, a total of 8,294 calls are received and responded via toll-free call centers.

Phone Follow-Up of Travelers

- As of April 10, 2020:
 - 125 travelers and discharged suspects are under follow-up.
 - 3,361 travelers (9 new) have completed 14 days of follow-up and graduated from follow-up.
 - There is no alert case detected during follow up as of today.

Quarantined passengers follow up

- As of April 10, 2020; a total of 1,936 travelers are under mandatory quarantine at designated Hotels.
- No alert case identified from passengers under quarantine.
- Laboratory test results delivered for 524 people who were finalized the 14 days mandatory quarantine period and have been waiting for the test result

PASSENGERS SCREENING

- A total of 3,055 passengers arrived into the country since March 23, 2020
- Discussion has been made on possible designation of Mental Health treatment site and volunteer for Psychosocial support for all quarantine sites.
- Follow-up of the mandatory quarantine implementation for passengers coming from abroad via BIA in ongoing.
- Health screening for arriving international passengers is ongoing.

CASE MANAGEMENT AND INFECTION PREVENTION AND CONTROL (IPC):

- There are 56 confirmed cases in the case treatment centers currently. Of these, three are under treatment in the designated treatment center in Bahir Dar, Amhara regional state and two are in Dire Dawa city administration
- There is no critical case and all are on medical care in stable condition.
- A total of ten people fully recovered
- 36 suspected cases are admitted today.
- 41 initially suspected cases are discharged after laboratory test became negative.
- There are 46 suspected cases in the isolation centers waiting for laboratory results.

LOGISTICS, ADMINISTRATION AND RELATED ACTIVITIES:

- National inventory of medical equipment is finalized.
- 90 infrared thermometers are sent to National Metrology Institute for calibration.
- 15 health professionals deployed and PPE provided to 6 kilo main campus quarantine site

RISK COMMUNICATION:

- 200 posters and 500 brochures of COVID-19 messages are distributed to the Ministry of Education.
- Social mobilization on COVID-19 has been conducted using mobile vans at Addis Ababa Science and Technology (AASTU) and civil service returnees' sites.
- Press release on newly confirmed COVID-19 cases shared for the public.

MEDIA / WEB SCANNING:

Studies on treatment of COVID-19:

- Hydroxychloroquine and azithromycin as a treatment of COVID-19 (1).

- In a non-randomized clinical trial provision of 600mg of hydroxychloroquine daily and viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment.
- Twenty cases were treated in this study and showed a significant reduction of the viral carriage compared to controls.
- Azithromycin was significantly more efficient for virus elimination.
- The survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.

- Hydroxychloroquine, a less toxic derivative of chloroquine (2).

- This study showed that Hydroxychloroquine (HCQ) against SARS-CoV-2 infection in comparison to chloroquine (CQ) in vitro can efficiently inhibit SARS-CoV-2 infection.
- Authors predict that HCQ has a good potential to combat the disease. However, this waits confirmation by clinical trials.
- It is also pointed out, although HCQ is less toxic than CQ, prolonged and overdose usage can still cause poisoning.
- The effective dose of HCQ and the ideal treatment duration and time of therapy initiation throughout the clinical course of COVID-19 remains unknown.

- Efficacy of hydroxychloroquine in patients with COVID-19 (3).

- This study evaluated the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19.
- Time to clinical recovery (TTCR), the body temperature recovery time and the cough remission time were significantly shortened in the HCQ treatment group.
- A larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 32) compared with the control group (54.8%, 17 of 32).
- All 4 patients progressed to severe illness in the control group and there were 2 patients with mild adverse reactions in the HCQ treatment group.
- The study concluded, among patients with COVID-19 the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia.

- High-dose intravenous immunoglobulin as a therapeutic option (4).

- Three patients with severe COVID-19 treated with high-dose intravenous immunoglobulin (IVIG) were described in this study.
- All experienced resolution of fever within 1-2 days and oropharyngeal swab viral nucleic acid negativity within 4-5 days of IVIG initiation.
- Patient 2 received lopinavir/ritonavir and patient 3 received concomitant methylprednisolone so the role of IVIG in the clinical course of these patients is unclear.
- Thus, use of IVIG for treatment of COVID-19 remains debatable, particularly when current IVIG formulations would not be expected to contain antibodies for SARS-CoV-2.

Summary

- Although data are emerging on the potential therapeutic options, the quality of the evidence remains weak and firm conclusions cannot be made.
- It should be noted that proven safe and effective therapy is currently limited to supportive care.
- Carefully designed clinical trials are needed.

- In settings where clinical trials are not a realistic option all members of the health care team are obligated to assess emerging data and make informed, safe, team-based decisions to allow patients the best opportunity for a positive prognosis.

References:

1. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial PhilippeGautret, Jean-ChristopheLagier, PhilippeParola, Van ThuanHoang et.al <https://doi.org/10.1016/j.ijantimicag.2020.105949>
2. Liu, J., Cao, R., Xu, M. *et al.* Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov* **6**, 16 (2020). <https://doi.org/10.1038/s41421-020-0156-0>
3. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Zhaowei Chen, Jijia Hu, Zongwei Zhang, Shan Jiang, Shoumeng Han, Dandan Yan, Ruhong Zhuang, Ben Hu, Zhan Zhang. doi: <https://doi.org/10.1101/2020.03.22.20040758>
4. Wei Cao, M.D, Xiaosheng Liu, PhD, Tao Bai, M.D, Hongwei Fan, M.D, Ke Hong, M.D, Hui Song, M.D, Yang Han, PhD, Ling Lin, M.D, Lianguo Ruan, M.D, Taisheng Li, M.D, PhD, High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019, *Open Forum Infectious Diseases*, ofaa102, <https://doi.org/10.1093/ofid/ofaa102>

8335 / 952



Call-Centers
FOR MORE INFO and
ALERT NOTIFICATION on
COVID-19



The above presented Quick Reader (QR) code takes you to a portal that you can access updates and all COVID-19 related information available
(<https://www.eph.gov.et/index.php/public-health-emergency/novel-corona-virus-update>)

DISCLAIMER

Figures presented in this situation report are pulled from official releases of the World Health Organization,
Other sources from the web, as well as report compiled by the National Incidence Response Team

PREPARED BY

Fantu Lombamo (MD, MPH) and Negusse Yohannis (PhD)
National PHEOC, Planning Section

CONTRIBUTORS

Firmaye Bogale (Planning Section, PHEOC)

EDITED and REVIEWED BY

Shambel Habebe (Planning Section Chief) and
Zewdu Assefa (COVID-19 Deputy Incident Manager)

FOR MORE INFORMATION and NOTIFICATION

Web: www.eph.gov.et

Follow us on Twitter: @EPHIethiopia

Call: 8335 (TOLL FREE LINE) or 011 276 5340

Email: ephieoc@gmail.com or pheodatacenter@gmail.com

ETHIOPIAN PUBLIC HEALTH INSTITUTE

National Public Health Emergency Operation Center
Center for Public Health Emergency Management

WITH A TECHNICAL ASSISTANCE FROM



**World Health
Organization**

ETHIOPIA COUNTRY OFFICE